Two approaches to downstaging muscle-invasive bladder cancer prior to radical cystectomy include neoadjuvant chemotherapy and transurethral resection.
Findings from a large study of bladder-sparing treatments for muscle-invasive bladder cancer support the routine use of 5-fluorouracil and mitomycin C concomitantly with radiation therapy.
In a phase 2 trial, more than half of patients who received neoadjuvant chemotherapy for high-risk upper tract urothelial carcinoma had a pathologic response that was associated with improved survival.
In a study, nearly 1 in 10 cancer patients on systemic therapy experienced an episode of acute kidney injury.
Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment.
Study findings suggest that clinicians should use neoadjuvant chemotherapy in many more muscle-invasive bladder cancer patients.
One-year overall survival of 61% for gemcitabine and cisplatin plus ipilimumab.
Among patients with short-term peripherally inserted central catheter, about 1 in 10 has a complication
Better reimbursement at hospital outpatient depts, even though drug-level costs lower in doctor’s office
Certain chemotherapies might shorten telomeres and alter microRNA.
